Research and Markets: Roche/Genentech/Novartis’ Asthma Treatment – Xolair … – Business Wire (press release)

Research and Markets: Roche/Genentech/Novartis' Asthma Treatment – Xolair
Business Wire (press release)
Roche/Genentech/Novartis' Xolair (omalizumab) is currently the only FDA-approved biologic used in the treatment of asthma. This drug is a recombinant humanized mAb that binds and neutralizes IgE with the same high affinity as its cognate receptor, FceRI.
Research and Markets: Merck's Dulera Asthma Treatment – Forecast and Market DigitalJournal.com

all 2 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.